

### **REMARKS**

#### **Status of the Claims**

Claims 1, 4, 6-10, 15, 16 and 20-22 are pending.

Claims 1, 4, 6-10, 15, and 20 have been rejected under 35 U.S.C. 112, first and second paragraphs.

Claims 16, 21 and 22 are allowed.

Claim 6 is objected to.

#### **Rejections under 35 U.S.C. 112**

The Examiner has maintained the rejection of Claims 1, 4, 6-10, 15 and 20 for misspelling heterocyclo (9/21/2007 Office action, point 4, original rejection 7g); and for not specifying the attachment of certain moieties (9/21/2007 Office action, point 2, original rejection 5b). In addition, the definitions of T<sup>1</sup>, T<sup>2</sup> and T<sup>3</sup> have been rejected as being vague and indefinite as there were no such variables in presently amended Formula (I) (9/21/2007 Office action, point 4, original rejection 7f).

In response, the spelling of “heterocyclo” (claim 1, subparagraph (i)) and moiety attachments have been designated as would be understood by one of skill in the art (Specification and claims 1 and 6, subparagraph (i)). Also, the now superfluous definitions of T<sup>1</sup>, T<sup>2</sup> and T<sup>3</sup> have been deleted from claims 1 and 6. Accordingly, Applicants request withdrawal of the rejections under 35 U.S.C. 112.

#### **Objection**

Claim 6 was objected to as there was no variable R<sup>6</sup> in Formula (Ia). In response, variable R<sup>6</sup> has been canceled in claim 6 and withdrawal of the objection is requested. Applicants believe that the amendments presented herein do not add new matter or broaden the scope of what is claimed.

In summary, Applicants believe the rejections and/or objection to the claims have been either addressed or rendered moot and that the claims are now in condition for allowance.

#### **FEES**

No fee should be due, however, if it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

The Examiner is invited to contact the undersigned by telephone, at the number listed below, if it is believed that a telephonic communication would facilitate the prosecution of this application.

**Serial No. 10/702,295**  
**Attorney Docket No. QA0253 NP**

Respectfully submitted,

Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-5323

/Laurelee A. Duncan, Reg. No. 44,096/  
Attorney for Applicants  
Reg. No. 44,096

Date: November 20, 2007